Skip to main content
. Author manuscript; available in PMC: 2016 Mar 1.
Published in final edited form as: Adv Anat Pathol. 2015 Mar;22(2):94–101. doi: 10.1097/PAP.0000000000000049

FIG. 2. FGFR1 and BRAF alterations in pediatric LGG converge on the MAP kinase pathway.

FIG. 2

Alterations in FGFR1 result in constitutive activation of the receptor resulting in activation of the MAP kinase pathway. A subset of pediatric LGG also shows mutations in the receptor tyrosine kinase NTRK2. Rare mutations involve other members of this pathway including RAS, NF1 (negative regulator of RAS) and PTPN11, a tyrosine phosphatase adaptor protein. BRAF V600E mutations and the BRAF-KIAA1549 fusion (other rare fusions not illustrated) also result in constitutive kinase activity and aberrant MAP kinase activation. Text in red indicates mutations/alterations.